In this medfyle

LBCL remains a challenge in oncology, with 25% to 35% of patients not achieving a cure through standard frontline treatment. R-CHOP has been the mainstay for two decades, but recent advancements, such as the pola-R-CHP regimen, are finally challenging its frontline position. Over 15 promising randomized trials are currently exploring new treatment options tailored to specific biological subtypes and high-risk populations, as well as response-adapted approaches like ctDNA tracking. While this variety raises hopes for improved outcomes, it also introduces complexities in determining the best treatment strategies if multiple trials succeed. The next few years will be pivotal in re-shaping LBCL frontline therapy.